Skip to content

Diabetic Gastroparesis

NO LONGER ACCEPTING APPLICATIONS
Published on:
September 18, 2024
Sign-up Expiration:
Updated:
Topics:
Locations:

Assess the ability of CIN-102 to significantly decrease the severity of gastroparesis-related symptoms as compared to baseline in adult subjects with diabetic gastroparesis, based on a composite of the average ANMS GCSI-DD Nausea Sub-Scale and Vomiting Severity Scores over the last 2 weeks of the 12-week Treatment Period, compared to placebo.

View Additional Information
View Clinical Trial Attachment
Sign Up NowExpired - View Other Trials
ENDED